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Abstract:
Background and Objectives: The purpose of  this study was to compare the effects of  phosphate binders lanthanum carbon-
ate (LC) versus sevelamer hydrochloride (SH) in end-stage renal disease (ESRD) patients undergoing hemodialysis.
Methods: Studies including randomized controlled trials (RCTs) comparing phosphate binders lanthanum carbonate versus 
sevelamer hydrochloride, in ESRD patients undergoing hemodialysis, were identified using a pre-defined search strategy. Phos-
phate, calcium, calcium-phosphorus product, intact parathyroid hormone, alkaline phosphatase, total cholesterol, and triglycer-
ide were extracted and compared by RevMan 5.1 (The Cochrane Collaboration, Oxford, UK).
Results: Six studies were identified. Meta-analysis showed that SH treatment reduced levels of  phosphate, intact parathyroid 
hormone, and total serum alkaline phosphatase (ALP) when compared with LC treatment. Furthermore, patients on SH treat-
ment tended to have reduced calcium levels, calcium-phosphorus product, total cholesterol, and triglyceride when compared to 
patients treated with LC, but there was no statistical difference.
Conclusion: SH treatment of  patients with ESRD is more effective compared to LC treatment. However, more well-designed 
random control trails are required for confirmation. 
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Patients with End State Renal Disease (ESRD) present 
very late and with cardiovascular complications, and have 
refractory hypertension, anemia, and other complica-
tions, such as chronic kidney disease mineral bone dis-
order (CKD-MBD), with very high morbidity and mor-
tality1-4. High serum phosphorus is linked to poor health 
and mortality in chronic kidney disease (CKD) patients 
undergoing dialysis5. Kidney Foundation Kidney Disease 
Outcome Quality Initiative (KDOQI) 2003 guidelines 
recommend maintaining phosphorus levels between 3.5 
and 5.5 mg/dL in dialysis patients, and more than half  of  
dialysis patients have serum phosphorus levels above the 
range recommended by the KDOQI6,7. Elevated phos-
phorus is associated with increased mortality in patients 
with end-stage renal disease (ESRD)8. Hyperphosphate-
mia in patients with ESRD is common among recipients 
of  maintenance dialysis and is associated with a higher 
risk of  mortality and cardiovascular events9. Prevention 
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or management of  rising or high serum phosphate con-
centrations in CKD patients is now considered to be an 
important intervention to prevent downstream complica-
tions resulting from poor management of  serum calcium 
and parathyroid hormone (PTH)10.
Oral phosphate binders are prescribed to CKD patients to 
prevent the absorption of  dietary phosphate, conferring 
a significant survival benefit to dialysis patients, as does 
the use of  dietary phosphate binders11. Currently avail-
able binders have been associated with either impaired 
(calcium-based binders) or beneficial (non-calcium-based 
binders) outcomes. Commonly used calcium-containing 
phosphate binders may contribute to calcium overload, 
potentially increasing the risk of  vascular calcification and 
cardiovascular disease. Lanthanum carbonate (LC) and 
sevelamer hydrochloride (SH) are two of  the most im-
portant non-calcium-based binders at present. Non-cal-
cium-containing phosphate binders are advocated for pa-
tients with evidence of  hypercalcemia, serum parathyroid 
hormone (PTH) values < 150 pg/ml, and vascular or soft 
tissue calcification7.
However, it has been difficult for the doctors to choose 
between LC and SH for treatment of  ESRD patients. 
This meta-analysis was performed to assess the differ-





The relevant studies were screened, from the search en-
gines of  PubMed, Embase, and Cochrane Library as of  
31 March 2017, using the search terms “(Lanthanum 
Carbonate OR LC) AND (Sevelamer Hydrochloride OR 
SH)” without language limitation. We also extended the 
search spectrum to the ‘related articles’ and the bibliog-
raphies of  all retrieved studies. If  multiple publications 
from the same study group occurred, we only recruited 
the most complete paper for analysis.
 
Inclusion and exclusion criteria
Inclusion criteria
The inclusion criteria for the study were as follows: (1) 
study type: randomized controlled trials, randomized 
crossover study, prospective study, and case control study. 
(2) Object of  the study: all patients who met the diagnos-
tic criteria for ESRD. (3) Interventions: using lanthanum 
carbonate and sevelamer hydrochloride for treatment, re-
spectively. (4) Baseline information: comparable.
 
Exclusion criteria
Exclusion criteria for the study were as follows: (1) only 
used one drug for the treatment. (2) compared the lan-
thanum carbonate/sevelamer hydrochloride with other 




Phosphate (mg/dL), calcium (mg/dL), calcium-phos-
phorus product (mg2/dL2),intact parathyroid hormone 
(pg/mL), alkaline phosphatase (U/L), total cholesterol. 




Inclusion of  each study was agreed upon by two observ-
ers independently according to pre-determined inclusion 
criteria. Titles and abstracts were scanned first to make a 
list of  possibly related literature, and then the full texts 
were obtained for those articles identified as either rele-
vant or not clear, only randomized controlled trials, ran-
domized crossover studies, prospective studies, and case 
control studies fitting the pre-defined inclusion criteria 




Statistical analysis was performed by RevMan 5.1. The 
pooled statistics were calculated using the fixed effect 
model, but a random effect model was conducted if  the 
p-value of  the heterogeneity test was less than 0.1. Re-
sults are expressed with odds ratios (OR) for dichoto-
mous data, and weighted mean differences (WMD) for 
continuous data, and 95% confidence intervals (CI) were 
also calculated. Heterogeneity between included studies 




In this meta-analysis, six studies7,12-16 were included, and 
were comprised of  four randomized crossover stud-
ies7,12-14 and two prospective studies15,16 (Table 1). These 
six studies contained 370 SH cases and 306 LC controls 
(Table 1).
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Phosphate levels between the SH- and LC-treated 
groups
Six reports7,12-16 were included in this meta-analysis for the 
phosphate levels between SH- and LC-treated groups. The 
p-value of  the heterogeneity test was less than 0.00001, 
so a random effect model was conducted. The pooled 
mean difference was -0.15 (95% CI: -0.29 to -0.02). The 
difference in phosphate levels was statistically significant 
between SH group and LC group (p=0.03) (Fig. 1).
 
 
Figure 1. Phosphate levels between the SH-treated and LC-treated groups. 
Calcium levels do not differ between the SH and LC 
treatment groups
Six reports7,12-16 were included in this meta-analysis for the 
calcium level between the SH- and LC-treated groups. The 
p-value of  the heterogeneity test was less than 0.00001 
and a random effect model was conducted. Pooled mean 
difference was -0.06 (95% CI: -0.16 to 0.03). The differ-
ence of  calcium levels was not statistically significant be-
tween SH group and LC group (p=0.19) (Fig. 2).
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Figure 2. Calcium levels between SH group and LC group 
Calcium-phosphorus product levels were similar be-
tween the SH and LC treatment groups
Three reports12,14,16 were included in this meta-analysis for 
the calcium-phosphorus product level between SH- and 
LC-treated patients. The p-value of  the heterogeneity 
test was less than 0.02, so a random effect model was 
conducted. The pooled mean difference was -0.76 (95% 
CI: -4.14 to 2.61). Differences in the calcium-phosphorus 
product level were not statistically significant between the 
SH group and LC group (p=0.66) (Fig. 3).
 
Figure 3. Calcium-phosphorus product between the SH and LC groups 
Intact parathyroid hormone level between SH group 
and LC group
Five reports7,12-14,16 were included in this meta-analysis for 
the intact parathyroid hormone level between the SH and 
LC groups. The p-value of  the heterogeneity test was less 
than 0.00001, so a random effect model was conducted. 
The pooled mean difference was -10.19 (95% CI: -13.36 
to -7.01). The difference in intact parathyroid hormone 
was statistically significant between SH group and LC 
group (p<0.00001) (Fig. 4).
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Figure 4. Intact parathyroid hormone levels between SH and LC groups 
Alkaline phosphatase levels between the SH-treated 
and LC-treated groups
Two reports12,16 were included in this meta-analysis for 
the alkaline phosphatase level following SH and LC treat-
ment. The p-value of  the heterogeneity test was less than 
0.95 and a fixed effect model was conducted. The pooled 
mean difference was -5.04 (95% CI: -8.06 to -2.03). Dif-
ference of  alkaline phosphatase level was statistically sig-




Figure 5. Alkaline phosphatase levels between the SH and LC groups 
Total cholesterol levels do not differ between 
SH-treated and LC-treated patients
Two reports13,14 were included in this meta-analysis for the 
total cholesterol level between SH-treated and LC-treated 
patients. The p-value of  the heterogeneity test was less 
than 0.96 and a fixed effect model was conducted. Pooled 
mean difference was -13.64 (95% CI: -43.14 to 15.87). 
Difference in total cholesterol level was not statistically 





Figure 6. Total cholesterol levels between the SH and LC groups. 
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Triglyceride levels between SH- and LC-treated pa-
tients do not differ
Two reports13,14 were included in this meta-analysis for 
the triglyceride levels following SH treatment vs. LC 
treatment. The p-value of  the heterogeneity test was less 
than 0.91, so a fixed effect model was conducted. The 
pooled mean difference was -4.70 (95% CI: -26.42 to 
17.02). Difference of  triglyceride level was not statistical-
ly significant between groups (p=0.67) (Fig. 7).
 
 
Figure 7. Triglyceride levels between the SH and LC groups. 
Discussion
In this meta-analysis, treatment with SH was found to 
lower phosphate levels to a greater extent than treatment 
with LC. Fixed model comparisons also supported this 
result, indicating that using SH to treat CKD patients, to 
control the phosphate level, is better than using LC. Cal-
cium levels were not statistically different between the SH 
and LC groups, but when the fixed model was used to 
assess this relationship, SH treatment did appear to lower 
calcium levels, compared to LC treatment (p<0.00001). 
More studies should be performed to confirm this asso-
ciation further.
The calcium-phosphorus product level between the SH 
groupand LC group in this meta-analysis indicated that 
SH treatment tended to lower the calcium-phosphorus 
product level when compared with LC treatment. How-
ever, the difference of  calcium-phosphorus product lev-
el was not statistically significant between SH group and 
LC group. However, when the fixed model was used to 
assess this relationship, SH treatment the difference in 
calcium-phosphorus product level was statistically sig-
nificant between SH group and LC group (p<0.00001). 
More studies should be performed to confirm this asso-
ciation in the future.
Increased intact parathyroid hormone level is one of  the 
most important risk factors for ESRD patients. In this 
meta-analysis, we found that the SH treatment could low-
er PTH levels as compared to LC treatment. Lowering of  
PTH by SH was confirmed in the fixed model, indicating 
that treating ESRD patients with SH can control PTH 
level better than LC.
Elevated total serum alkaline phosphatase (ALP) levels 
have also been associated with mortality in both the gen-
eral population and in dialysis patients17. Therefore, in 
this meta-analysis, we examined ALP levels in SH-treated 
and LC-treated patients. We found that both the mean 
difference and fixed model show SH lowers ALP levels 
to a greater extent than LC. Therefore, using SH to treat 
CKD patients should better control ALP levels than us-
ing LC.
Examination of  total cholesterol level, another risk fac-
tor for patients with ESRD, showed that the difference 
of  total cholesterol level is not statistically significant be-
tween SH-treated vs. LC-treated patients. However, the 
pooled mean difference and fixed model indicate that the 
SH could lower total cholesterol level to a greater extent 
than LC. However, there were only two included studies 
for the meta-analysis on total cholesterol level. 
African Health Sciences Vol 18 Issue 3, September, 2018 694
Commonly elevated triglyceride levels are also a risk fac-
tor for the patients with ESRD. In this meta-analysis, 
there was no heterogeneity among the included studies, 
and the fixed model was chosen. The results from the 
pooled mean difference indicated the difference of  total 
triglyceride levels was not statistically significant between 
SH group and LC group. There were only two included 
studies for the meta-analysis on total triglyceride levels. 
SH and LC, non-aluminum and non-calcium phosphate 
binders, are used to prevent hyperphosphatemia without 
causing elevated serum calcium and causing and accel-
erating vascular calcification in CKD patients18-20. They 
bind with dietary phosphorus in the gastrointestinal tract 
and interrupts mucosal absorption. There is minimal ab-
sorption of  SH and LC into the gastrointestinal mucosa; 
therefore, its use in clinical practice does not cause organ 
failure18,21. Alam et al22 reported SH to be superior to cal-
cium-based phosphate binders in reducing serum calci-
um, phosphate, uric acid and LDL cholesterol levels in 
patient population with advanced renal bone disease, and 
SH also appears to be well tolerated with no significant 
side effects. Wang et al23 reported that compared with 
standard therapy (calcium-based phosphate binders), LC 
reduced all-cause mortality in patients on hemodialysis 
but did not decrease the risk of  cardiovascular events. The 
decrease in serum phosphorus level was similar between 
LC and the calcium-based phosphate binders, but the risk 
of  hypercalcemia was lower in patients who received LC. 
There was no meta-analysis to compare the effects of  
phosphate binders LC versus SH in ESRD patients un-
dergoing hemodialysis using meta-analysis method.
Conclusion
We conclude that SH treatment in ESRD patients bene-
fits more, compared to LC treatment, as based on great-
er reductions of  phosphate, calcium, intact parathyroid 
hormone, and alkaline phosphatase levels. Furthermore, 
treatment with SH would avoid the lanthanum accumu-
lation that occurs when the LC is used to treat ESRD 
patients for a prolonged time.
We recommend the use of  SH in patients with ESRD. 
However, more well designed, random controlled Trails 
should be performed.
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